Regen BioPharma, Inc.
RGBP
$0.01
$0.00-1.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | -25.80% | 43.67% | -10.35% | 35.02% | 35.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.24% | 7.68% | -33.77% | 22.95% | 15.81% |
| Operating Income | 62.22% | -12.07% | 50.00% | -46.19% | -26.76% |
| Income Before Tax | -28.59% | 84.16% | -255.69% | 18.49% | -31.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.59% | 84.16% | -255.69% | 18.49% | -31.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.59% | 84.16% | -255.69% | 18.49% | -31.15% |
| EBIT | 62.22% | -12.07% | 50.00% | -46.19% | -26.76% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 77.35% | 96.98% | -211.17% | 15.56% | -110.20% |
| Normalized Basic EPS | 77.20% | 96.77% | -211.11% | 27.38% | -109.78% |
| EPS Diluted | 77.35% | 96.98% | -211.17% | 15.56% | -110.20% |
| Normalized Diluted EPS | 77.20% | 96.77% | -211.11% | 27.38% | -109.78% |
| Average Basic Shares Outstanding | 463.71% | 424.41% | 14.30% | 11.89% | -37.69% |
| Average Diluted Shares Outstanding | 463.71% | 424.41% | 14.30% | 11.89% | -37.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |